| Symbol | REPL |
|---|---|
| Name | REPLIMUNE GROUP, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 500 UNICORN PARK,3RD FLOOR, WOBURN, Massachusetts, 01801, United States |
| Telephone | +1 781 222-9600 |
| Fax | — |
| — | |
| Website | https://www.replimune.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001737953 |
| Description | Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. Additional info from NASDAQ: |
(30% Negative) REPLIMUNE GROUP, INC. (REPL) Reports Q2 2026 Financial Results
Read moreNew Form S-8 - Replimune Group, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001104659-26-078583 <b>Size:</b> 254 KB
Read moreNew Form 10-K - Replimune Group, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001628280-26-045886 <b>Size:</b> 9 MB
Read moreReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Read moreSarchi Christopher 🔴 sold 12.0K shares of Replimune Group, Inc. (REPL) at $9.24 Transaction Date: Jun 01, 2026 | Filing ID: 070256
Read moreReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Read moreReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Read more(99% Neutral) REPLIMUNE GROUP, INC. (REPL) Announces Enrollment Update for need Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations
Read moreReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Read more